Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Board Change

5th Sep 2018 07:00

RNS Number : 7576Z
Amphion Innovations PLC
05 September 2018
 

 

Amphion Innovations plc

 ("Amphion" or "the Company")

 

Board Change

 

London and New York: 5 September 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses announces the appointment of Stephen Austin as an additional non-executive director effective immediately. Following a career as a corporate lawyer, qualified executive and corporate stockbroker, Stephen is now the Chief Investment Officer of Plumtree Capital Limited, an FCA authorised corporate finance firm.

 

Stephen will join the Compensation Committee (as chairman) and the Audit Committee.

 

Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.

 

Stephen Michael Austin (age 51) is, or has been in the previous five years, a director or partner, of the following companies:

 

Current appointments

Past appointments

EC Aquisitions plc

Wisdom Acquisitions plc

Plumtree Capital Limited

 

Plumtree Opportunities Limited

 

Plumtree Small Cap Credit LLP

 

 

Stephen Austin currently owns 300,000 warrants in the Company. The warrants have an exercise price of 3.5 pence and expire 28 July 2019.

 

Richard Morgan, CEO, commented: "We have worked with Stephen for four years on a range of projects including the successful AIM IPOs of Motif Bio and Polarean Imaging and now welcome him to the Board."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

 

For further information please contact:

 

Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Freddy Crossley / Emma Earl (Corporate Finance)

Charlie Leigh-Pemberton (Corporate Broking)

Northland Capital Partners Limited (Joint Corporate Broker)

Tel: +44 (0)20 3861 6625

David Hignell (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy / Paul McManus

About Amphion Innovations plc

 

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

 

On the web: www.amphionplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAFKQDQPBKDACK

Related Shares:

AMP.L
FTSE 100 Latest
Value8,275.66
Change0.00